KBL Merger Corp. IV KBLM on Friday announced its acquisition of a new cannabis biotech company CannBioRx Life Sciences Corp.
CannBioRx Life Sciences Corp. has three synergistic programs that operate at the intersection of biotech and cannabis, and focuses on developing novel anti-inflammatory drugs for diseases like Crohn's and multiple sclerosis.
Benzinga's Cannabis Capital Conference heads to Detroit on Aug. 15 -- Click here to learn more!
The company was founded by Sir Marc Feldmann of Oxford and Lawrence Steinman of Stanford, who have significant expertise in developing successful therapeutics that resulted in billion-dollar markets, including blockbusters like Johnson & Johnson JNJ’s Remicade.
"We expect to be one of a limited number of NASDAQ-listed companies developing non-plant-touching, pharmaceutical-grade, non-psychoactive cannabinoids. These drugs are intended to provide safer, uniform dosing, according to regulatory agency standards," said Dr. Marlene Krauss, CEO of KBLM, who will also assume the role of CEO of CannBioRx Life Sciences Corp.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Click on the image for more info.
Cannabis rescheduling seems to be right around the corner
Want to understand what this means for the future of the industry?
Hear directly for top executives, investors and policymakers at the Benzinga Cannabis Capital Conference, coming to Chicago this Oct. 8-9.
Get your tickets now before prices surge by following this link.